OBJECTIVES: This study sought to identify genetic modifiers of beta-blocker response and long-term survival in heart failure (HF). BACKGROUND: Differences in beta-blocker treatment effect between Caucasians and African Americans with HF have been reported. METHODS: This was a prospective cohort study of 2,460 patients (711 African American, 1,749 Caucasian) enrolled between 1999 and 2007; 2,039 patients (81.7%) were treated with a beta-blocker. Each was genotyped for beta1-adrenergic receptor (ADRB1) Arg389>Gly and G-protein receptor kinase 5 (GRK5) Gln41>Leu polymorphisms, which are more prevalent among African Americans than Caucasians. The primary end point was survival time from HF onset. RESULTS: There were 765 deaths during follow-up (median 46 months). beta-blocker treatment increased survival in Caucasians (log-rank p = 0.00038) but not African Americans (log-rank p = 0.327). Among patients not taking beta-blockers, ADRB1 Gly389 was associated with decreased survival in Caucasians (hazard ratio [HR]: 1.98, 95% confidence interval [CI]: 1.1 to 3.7, p = 0.03) whereas GRK5 Leu41 was associated with improved survival in African Americans (HR: 0.325, CI: 0.133 to 0.796, p = 0.01). African Americans with ADRB1 Gly389Gly GRK5 Gln41Gln derived a similar survival benefit from beta-blocker therapy (HR: 0.385, 95% CI: 0.182 to 0.813, p = 0.012) as Caucasians with the same genotype (HR: 0.529, 95% CI: 0.326 to 0.858, p = 0.0098). CONCLUSIONS: These data show that differences caused by beta-adrenergic receptor signaling pathway gene polymorphisms, rather than race, are the major factors contributing to apparent differences in the beta-blocker treatment effect between Caucasians and African Americans; proper evaluation of treatment response should account for genetic variance.
OBJECTIVES: This study sought to identify genetic modifiers of beta-blocker response and long-term survival in heart failure (HF). BACKGROUND: Differences in beta-blocker treatment effect between Caucasians and African Americans with HF have been reported. METHODS: This was a prospective cohort study of 2,460 patients (711 African American, 1,749 Caucasian) enrolled between 1999 and 2007; 2,039 patients (81.7%) were treated with a beta-blocker. Each was genotyped for beta1-adrenergic receptor (ADRB1) Arg389>Gly and G-protein receptor kinase 5 (GRK5) Gln41>Leu polymorphisms, which are more prevalent among African Americans than Caucasians. The primary end point was survival time from HF onset. RESULTS: There were 765 deaths during follow-up (median 46 months). beta-blocker treatment increased survival in Caucasians (log-rank p = 0.00038) but not African Americans (log-rank p = 0.327). Among patients not taking beta-blockers, ADRB1Gly389 was associated with decreased survival in Caucasians (hazard ratio [HR]: 1.98, 95% confidence interval [CI]: 1.1 to 3.7, p = 0.03) whereas GRK5Leu41 was associated with improved survival in African Americans (HR: 0.325, CI: 0.133 to 0.796, p = 0.01). African Americans with ADRB1Gly389GlyGRK5Gln41Gln derived a similar survival benefit from beta-blocker therapy (HR: 0.385, 95% CI: 0.182 to 0.813, p = 0.012) as Caucasians with the same genotype (HR: 0.529, 95% CI: 0.326 to 0.858, p = 0.0098). CONCLUSIONS: These data show that differences caused by beta-adrenergic receptor signaling pathway gene polymorphisms, rather than race, are the major factors contributing to apparent differences in the beta-blocker treatment effect between Caucasians and African Americans; proper evaluation of treatment response should account for genetic variance.
Authors: Christopher A Haiman; Nick Patterson; Matthew L Freedman; Simon R Myers; Malcolm C Pike; Alicja Waliszewska; Julie Neubauer; Arti Tandon; Christine Schirmer; Gavin J McDonald; Steven C Greenway; Daniel O Stram; Loic Le Marchand; Laurence N Kolonel; Melissa Frasco; David Wong; Loreall C Pooler; Kristin Ardlie; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Esther M John; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich Journal: Nat Genet Date: 2007-04-01 Impact factor: 38.330
Authors: Lu Chen; Deborah Meyers; George Javorsky; Darryl Burstow; Pakorn Lolekha; Margaret Lucas; Annalese B T Semmler; Santiyagu M Savarimuthu; Kwun M Fong; Ian A Yang; John Atherton; Andrew J Galbraith; William A Parsonage; Peter Molenaar Journal: Pharmacogenet Genomics Date: 2007-11 Impact factor: 2.089
Authors: Stephen B Liggett; Sharon Cresci; Reagan J Kelly; Faisal M Syed; Scot J Matkovich; Harvey S Hahn; Abhinav Diwan; Jeffrey S Martini; Li Sparks; Rohan R Parekh; John A Spertus; Walter J Koch; Sharon L R Kardia; Gerald W Dorn Journal: Nat Med Date: 2008-04-20 Impact factor: 53.440
Authors: Wayne Rosamond; Katherine Flegal; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan M Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Bret Kissela; Steven Kittner; Donald Lloyd-Jones; Mary McDermott; James Meigs; Claudia Moy; Graham Nichol; Christopher O'Donnell; Veronique Roger; Paul Sorlie; Julia Steinberger; Thomas Thom; Matt Wilson; Yuling Hong Journal: Circulation Date: 2007-12-17 Impact factor: 29.690
Authors: Rahul C Deo; Nick Patterson; Arti Tandon; Gavin J McDonald; Christopher A Haiman; Kristin Ardlie; Brian E Henderson; Sean O Henderson; David Reich Journal: PLoS Genet Date: 2007-11 Impact factor: 5.917
Authors: Michael A Pacanowski; Issam Zineh; Haihong Li; B Delia Johnson; Rhonda M Cooper-DeHoff; Vera Bittner; Dennis M McNamara; Barry L Sharaf; C Noel Bairey Merz; Carl J Pepine; Julie A Johnson Journal: J Transl Med Date: 2008-03-10 Impact factor: 5.531
Authors: Thomas P Cappola; Scot J Matkovich; Wei Wang; Derek van Booven; Mingyao Li; Xuexia Wang; Liming Qu; Nancy K Sweitzer; James C Fang; Muredach P Reilly; Hakon Hakonarson; Jeanne M Nerbonne; Gerald W Dorn Journal: Proc Natl Acad Sci U S A Date: 2011-01-19 Impact factor: 11.205
Authors: David E Lanfear; Tara N Hrobowski; Edward L Peterson; Karen E Wells; Tanmay V Swadia; John A Spertus; L Keoki Williams Journal: Circ Heart Fail Date: 2012-01-19 Impact factor: 8.790
Authors: Frank S Ong; Joshua L Deignan; Jane Z Kuo; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody; Kingshuk Das Journal: Pharmacogenomics Date: 2012-03 Impact factor: 2.533